# Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05577702/  
OnCo record `nct05577702` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Alcestobart run by BeiGene, completed.

## Summary

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05577702 by BeiGene, with 121 participants enrolled, started 2023-03-08. Conditions recorded: Non Small Cell Lung Cancer. Interventions recorded: Tislelizumab, Ociperlimab, Alcestobart, Cisplatin, Carboplatin, Pemetrexed and Paclitaxel.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05577702
- Phase: 2
- Setting: A Randomized, Open-Label, Multicenter, Phase 2, Umbrella Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations With and Without Chemotherapy as Neoadjuvant Treatment in Chinese Patients With Resectable Stage II to IIIA Non-Small Cell Lung Cancer
- Sponsor: BeiGene
- Enrolled: 121

## Sources

- ClinicalTrials.gov NCT05577702: https://clinicaltrials.gov/study/NCT05577702

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Alcestobart](https://onco.cc/drugs/alcestobart/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct05577702.json